Upgrade Risk in Intraductal Papillomas: A Retrospective Analysis of Real-World Data and Predictive Model Development
Kotola, Jenni (2026-03-16)
Upgrade Risk in Intraductal Papillomas: A Retrospective Analysis of Real-World Data and Predictive Model Development
(16.03.2026)
Julkaisu on tekijänoikeussäännösten alainen. Teosta voi lukea ja tulostaa henkilökohtaista käyttöä varten. Käyttö kaupallisiin tarkoituksiin on kielletty.
suljettu
Julkaisun pysyvä osoite on:
https://urn.fi/URN:NBN:fi-fe2026032422707
https://urn.fi/URN:NBN:fi-fe2026032422707
Tiivistelmä
Background: In current practice, the traditional strategy of excising all IDPs has been replaced by more selective management. However, criteria for selecting patients for surveillance remain unclear, and no widely accepted predictive model exists.
Methods: We retrospectively analyzed real-world data from 325 cases of IDPs diagnosed via core needle biopsy (CNB) at a tertiary teaching hospital between 2010 and 2023. We assessed upgrade rates to malignancy and evaluated potential predictive factors. Two previously published models were applied to our cohort, and a new model was developed based on our data.
Results: Overall, 17 % (55/325) of IDPs were upgraded to malignancy. Among lesions without atypia on CNB (n = 215), the upgrade rate was 8.8 % (19/215), compared to 40 % (23/58) in those with atypia (p < 0.001). Previously suggested models yielded modest results when applied to our study population. First model would have spared 11 % (24/215) of patients from surgery, while the second model would have spared 17 % (36/215), with one missed upgrade. Our model identified all upgraded cases and would have spared 33 % (72/215) of non-atypical IDPs from surgery.
Conclusions: Atypia on CNB is a strong predictor of upgrade to malignancy. Existing models showed limited utility in reducing unnecessary surgeries. Our proposed model demonstrated improved performance and may support more individualized management of IDPs.
Methods: We retrospectively analyzed real-world data from 325 cases of IDPs diagnosed via core needle biopsy (CNB) at a tertiary teaching hospital between 2010 and 2023. We assessed upgrade rates to malignancy and evaluated potential predictive factors. Two previously published models were applied to our cohort, and a new model was developed based on our data.
Results: Overall, 17 % (55/325) of IDPs were upgraded to malignancy. Among lesions without atypia on CNB (n = 215), the upgrade rate was 8.8 % (19/215), compared to 40 % (23/58) in those with atypia (p < 0.001). Previously suggested models yielded modest results when applied to our study population. First model would have spared 11 % (24/215) of patients from surgery, while the second model would have spared 17 % (36/215), with one missed upgrade. Our model identified all upgraded cases and would have spared 33 % (72/215) of non-atypical IDPs from surgery.
Conclusions: Atypia on CNB is a strong predictor of upgrade to malignancy. Existing models showed limited utility in reducing unnecessary surgeries. Our proposed model demonstrated improved performance and may support more individualized management of IDPs.